

# Arcadia Biosciences Inc

16:13 04 Mar 2019

## Buds & Duds: Arcadia Biosciences stock soars after earning Hawaii hemp license

Cannabis stocks had a rough day on Monday, echoing the widespread losses felt across Wall Street.

The North American Marijuana Index, which tracks leading cannabis stocks in the US and Canada, fell 1.8% to 286.5.

### Buds

Bucking the trend, shares of Arcadia Biosciences Inc (NASDAQ:RKDA) surged Monday after announcing it received its first industrial hemp license in Hawaii. The Davis, California-based company recently launched Arcadia Specialty Genomics, a unit dedicated exclusively to cannabis, which will begin research in April on a 10-acre facility. As a result, shares of the food ingredient company are up 11.1% to \$8.01.

Also trading higher was Vancouver-based Harvest One Cannabis Inc (CVE:HVT), which saw share prices jump 9.1% to \$0.72 after the company announced an agreement Monday to acquire biotech company Delivra Corp (TSXV:DVA) in a C\$19 million all-stock deal. Delivra's LivRelief brand produces topicals and creams, which Harvest One's CEO Grant Froese says will serve them well with cannabis-infused products expected to become legal in Canada this fall, per a press release from the two companies.

### Duds

Shares of Aurora Cannabis Inc. (NYSE:ACB) dipped 2.7% to \$7.14 amid a deal to acquire a stake in privately held Whistler Medical Marijuana. The Edmonton-based company will pay roughly US\$175 million to Cronos Group Inc (NASDAQ:CRON) for its 19% stake in Whistler, with Cronos getting about 2.5 million of Aurora common shares worth about C\$24.6 million.

Last September, Aurora was said to be in talks with The Coca-Cola Co (NYSE:KO) about a joint venture in CBD-infused beverages. Nothing has come to fruition yet, but analyst Rob Wertheimer of Melius Research has rated the company Overweight.

Falling even farther was Terra Tech Corp. (OTCMKTS:TRTC), whose shares dropped 12.8% to \$0.77. The Irvine, California-based company announced today that renovations of its cultivation facility in Oakland have been completed. Planting is expected to commence later this week, per a statement from the company.

Contact Andrew Kessel: [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter: [@andrew\\_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

**Price:** 5.06

**Market Cap:** \$43.6 m

### 1 Year Share Price Graph



October 2018    April 2019    October 2019

### Share Information

**Code:** RKDA

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	10.4	1.85

**Sector:** Agribusiness

**Website:** [arcadiabio.com](http://arcadiabio.com)

### Company Synopsis:

*Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).